Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionNwam Llc
Latest Disclosed Ownership6,332 shares
Latest Disclosed Value $ 2,827,491
Nwam Llc reports 25.68% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 4, 2026 - Nwam Llc filed a 13F-HR form disclosing ownership of 6,332 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $2,827,491 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 4, 2026 disclosing 5,038 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 25.68% during the quarter. The current value of the position is $2,712,249 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-04 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,332 1,294 25.68 2,827 18.04 0.1627
2026-02-04 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,038 -39 -0.77 2,395 13.03 0.1338
2026-02-04 2025-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 5,077 -10 -0.20 2,119 -8.66 0.1150
2025-10-28 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,766 -10 2,032 0.1429
2026-02-04 2025-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 5,087 345 7.28 2,320 0.91 0.1348
2025-08-07 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,776 34 2,241 0.1823
2025-05-05 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,742 -1,436 -23.24 2,299 -7.56 0.1977
2025-02-05 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,178 1,178 23.56 2,488 6.97 0.1538
2024-11-12 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,000 8 0.16 2,325 -0.60 0.1418
2024-07-24 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,992 132 2.72 2,340 17.30 0.6875
2024-05-09 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,860 -2 -0.04 1,994 0.81 0.1610
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,862 11 0.23 1,978 17.32 0.1589
2023-11-01 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,851 -10 -0.21 1,687 -1.40 0.1711
2023-08-10 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,861 -12 -0.25 1,711 11.40 0.1405
2023-05-12 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,873 -75 -1.52 1,535 7.49 0.1557
2023-02-08 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,948 30 0.61 1,429 0.28 0.1266
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,918 106 2.20 1,424 2.52 0.1359
2022-08-10 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,812 -961 -16.65 1,389 -7.83 0.1283
2022-05-12 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,773 -1 -0.02 1,507 18.85 0.1158
2022-02-10 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,774 3,339 137.13 1,268 186.88 0.1002
2021-11-03 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,435 2,435 442 0.0401
2020-10-16 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -1,169 -100.00 0 -100.00
2020-07-21 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,169 6 0.52 339 22.38 0.0475
2020-04-16 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,163 -100 -7.92 277 0.00 0.0075
2020-01-23 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,263 1,263 277 0.0479
2016-09-08 2013-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -7,434 -100.00 0 -100.00
2016-09-08 2012-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,434 1,861 33.39 311 0.00 0.1315
2016-09-08 2012-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,573 3 0.05 311 0.00 0.1306
2016-09-08 2012-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,570 5,570 311 0.1440
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.